Bone losses in obese, ovariectomized rats appear to be independent from sclerostin-induced inhibition of the Wnt/β-catenin pathway
More details
Hide details
Department of Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences, Lublin, Poland
Department of Gastroenterology of Clinical Hospital 2, University of Rzeszow, Poland
Department of Endoscopy, Institute of Rural Health, Lublin, Poland
Department of Orthopaedics and Traumatology, Medical University, Lublin, Poland
Chair of Oncology and Environmental Health Care, Faculty of Health Sciences, Medical University, Lublin, Poland
Marek Bieńko   

Department of Animal Physiology, Faculty of Veterinary Medicine,University of Life Sciences in Lublin, Poland, Akademicka 12, 20-950, Lublin
Overweight and obesity, as well as a gonadal function, are pivotal factors influencing bone tissue metabolism.

Material and methods:
The aim of the study was to determine the effect of dietary induced obesity (DIO) on bone tissue metabolism in sham-operated (SHO) or ovariectomized (OVX) adult female Wistar rats. Additionally, the influence of DIO in SHO or OVX on the concentration of sclerostin in the blood serum was analyzed. After SHO or OVX, the rats were placed in groups (n=8) and either received a standard diet (11.5 MJ/kg) (SHO-CON; OVX-CON) or a high-energy diet (17.6 MJ/kg) (SHO-FAT; OVX-FAT). The experiment lasted for 90 days and allowed for the establishment of osteopenia in OVX females and obesity in the rats that had received the high-energy diet.

The results of the study demonstrate that obesity or/and ovariectomy increases the resorption of femora and tibiae, hence decreasing the densitometric and mechanical parameters affecting the bone structure in adult females rats. The strongest osteodegenerative effect was seen in the OVX-FAT females. Interestingly, the degree of bone tissue degradation caused exclusively by ovariectomy was similar to that found in the obese sham-operated rats.

Bone losses invoked by DIO seem to be independent from the Wnt/β-catenin pathway inhibition induced by sclerostin. While further study is necessary, the obtained results suggest that the usage of sclerostin anti-body in the treatment of osteoporosis can be ineffective, and in obese patients the undertaking of such therapy should be reassessed.

Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, et al. The human obesity gene map: the 2005 update. Obesity (Silver Spring). 2006; 14(4): 529-644.
Haworth CM, Plomin R, Carnell S, Wardle J. Childhood obesity: genetic and environmental overlap with normal-range BMI. Obesity (Silver Spring). 2008; 16(7): 1585-90.
Ailhaud G. Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome. C R Biol. 2006; 329(8): 570-655.
Bieńko M, Lis A, Wolski D, Radzki RP. Relationships between bone tissue and fat tissue. Med Wet. 2016; 72(4): 217-24.
Wolski D, Michalik J, Bieńko M, Radzki RP. Effects of obesity on health condition with an emphasis on bone tissues disorders. Eur J Clin Exp Med. 2018; 16(2): 117-22.
De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005; 16(11): 1330-8.
Rezende Yanagihara G, Carminati Shimano R, Atsuko Tida J, Suzuki Yamanaka J, Yasuyo Fukada S, Mardegan Issa JP, et al. Influence of High-Fat Diet on Bone Tissue: An Experimental Study in Growing Rats. J Nutr Health Aging. 2017; 21(10): 1337-43.
Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005; 115(5): 911-9.
Sharifi M, Ereifej L, Lewiecki EM. Sclerostin and skeletal health. Rev Endocrine Metab Dis. 2015; 16(2): 149-156.
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20: 781-810.
Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008; 4(2): 68-75.
Kikuchi A, Yamamoto H, Sato A. Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol. 2009; 19(3): 119-29.
Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133(16): 3231-44.
Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95(5): 2248-53.
Choi HY, Dieckmann M, Herz J, Niemeier A. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One. 2009; 4(11): e7930.
Tatsumi S, Nagamoto K, Ogata M, Miyamoto K. [Bone and Nutrition. Sclerostin and bone metabolism]. Clinical calcium. 2015; 25(7): 1043-7.
Register TC, Hruska KA, Divers J, Bowden DW, Palmer ND, Carr JJ, et al. Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab. 2014; 99(1): 315-21.
Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012; 23(3): 1171-6.
Armamento-Villareal R, Sadler C, Napoli N, Shah K, Chode S, Sinacore DR, et al. Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. J Bone Mineral Res. 2012; 27(5): 1215-21.
Tubic B, Zeijlon R, Wennergren G, Obermayer-Pietsch B, Marild S, Dahlgren J, et al. Randomised study of children with obesity showed that whole body vibration reduced sclerostin. Acta Paediatrica. 2019; 108(3): 502-513.
National Research Council (US) Subcommittee on Laboratory Animal Nutrition. Nutrient Requirements of Laboratory Animals. Edition FR, editor. Washington (DC): National Academies Press (US); 1995.
Radzki RP, Bieńko M, Puzio I, Studziński T. Effect of oestradiol and tamoxifen on the mechanical parameters of the femora and humera in broiler chickens. Med Wet. 2003; 59(12): 1090-1094.
Narla RR, Ott SM. Bones and the sex hormones. Kidney Internat. 2018; 94(2): 239-42.
Zha XY, Hu Y, Pang XN, Zhu JH, Chang GL, Li L. The association between sex hormone-binding globulin gene polymorphism with bone mineral density. Steroids. 2016; 106: 9-18.
Cherif R, Mahjoub F, Sahli H, Cheour E, Vico L, Sakly M, et al. Positive Association of Obesity and Insulin Resistance With Bone Mineral Density in Tunisian Postmenopausal Women. J Clin Densitometry. 2018; 21(2): 163-71.
Savvidis C, Tournis S, Dede AD. Obesity and bone metabolism. Horm-Int J Endocrino. 2018; 17(2): 205-17.
Farr JN, Dimitri P. The Impact of Fat and Obesity on Bone Microarchitecture and Strength in Children. Calcified Tissue International. 2017; 100(5): 500-13.
Gao F, Lv TR, Zhou JC, Qin XD. Effects of obesity on the healing of bone fracture in mice. J Orthopaedic Surg Res. 2018; 13(1): 145.
Chen ZB, Liu H, Li W, Jia SN, Zhang Y, Li BB. Correlation between obesity and bone health in Chinese children and adolescents. Inter J Clin Exp Med. 2017; 10(3): 5270-7.
Leslie WD, Morin SN, Majumdar SR, Lix LM. Effects of obesity and diabetes on rate of bone density loss. Osteoporosis Int. 2018; 29(1): 61-7.
Li W, Xu P, Wang CZ, Ha XD, Gu YJ, Wang Y, et al. The effects of fat-induced obesity on bone metabolism in rats. Obes Res Clin Pract. 2017; 11(4): 454-63.
Cao JJ, Gregoire BR, Gao H. Obesity Induced by High Dietary Fat Leads to Increased Bone Resorption Marker, TRAP, and Decreased Bone Mass in Mice. J Bone Min Res. 2008; 23: S432-S.
Radzki RP, Bieńko M, Filip RS. Influence of strontium ranelate on mineral and mechanical properties of the femur in orchidectomized rats. Med Wet. 2007; 63(12): 1630-1634.
Urasopon N, Hamada Y, Cherdshewasart W, Malaivijitnond S. Preventive effects of Pueraria mirifica on bone loss in ovariectomized rats. Maturitas. 2008; 59(2).
Ferretti M, Cavani F, Roli L, Checchi M, Magaro MS, Bertacchini J, et al. Interaction among Calcium Diet Content, PTH (1-34) Treatment and Balance of Bone Homeostasis in Rat Model: The Trabecular Bone as Keystone. Int J Mol Sci. 2019; 20(3).
Radzki RP, Bieńko M, Pierzynowski SG. Anti-osteopenic effect of alpha-ketoglutarate sodium salt in ovariectomized rats. J Bone Miner Metab. 2012; 30(6): 651-659.
Dobrowolski P, Tomaszewska E, Radzki RP, Bieńko M, Wydrych J, Zdybel A, et al. Can 2-oxoglutarate prevent changes in bone evoked by omeprazole? Nutrition. 2013; 29(3): 556-61.
Saxon LK, Turner CH. Estrogen receptor beta: the antimechanostat? Bone. 2005; 36(2): 185-192.
Seidlova-Wuttke D, Nguyen BT, Wuttke W. Long-term effects of ovariectomy on osteoporosis and obesity in estrogen-receptor-beta-deleted mice. Comp Med. 2012; 62(1): 8-13.
Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T, et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol. 2003; 149(4): 351-62.
Mosekilde L, Mosekilde L, Danielsen CC. Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals. Bone. 1987; 8(2): 79-85.
Ciarelli TE, Fyhrie DP, Schaffler MB, Goldstein SA. Variations in three-dimensional cancellous bone architecture of the proximal femur in female hip fractures and in controls. J Bone Miner Res. 2000; 15(1): 32-40.
Dempster DW. The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res. 2000; 15(1): 20-3.
Knott L, Bailey AJ. Collagen cross-links in mineralizing tissues: A review of their chemistry, function, and clinical relevance. Bone. 1998; 22(3): 181-7.
Lewiecki EM. Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis. 2014; 6(2): 48-57.
Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2017; 96: 63-75.
Rachner TD, Hofbauer L, Gobel A, Tsourdi E. Novel therapies in osteoporosis: PTH-related peptide analogues and inhibitors of sclerostin. J Mol Endocrinol. 2019; 62(2): R145-R154.